Table 6.
SNP ID | Gene | Genotype | HD | DL | GI | FA | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) OR (95% CI)a |
P-value P-valuea |
Q-value |
OR (95% CI) OR (95% CI)a |
P-value P-valuea |
Q-value |
OR (95% CI) OR (95% CI)a |
P-valueP-valuea | Q-value |
OR (95% CI) OR (95% CI)a |
P-valueP-valuea | Q-value | |||
rs2153364 | EGLN1 | AA | 1.26 (0.84–1.90) | 0.270 | 0.250 | 1.39 (0.93–2.08) | 0.110 | 0.098 | 1.29 (0.81–2.06) | 0.270 | 0.540 | 1.26 (0.85–1.87) | 0.250 | 0.220 |
AG/GG | 1.28 (0.84–1.93) | 0.250 | 1.41 (0.94–2.11) | 0.098 | 1.29 (0.81–2.07) | 0.270 | 1.28 (0.86–1.91) | 0.220 | ||||||
rs6756667 | EPAS1 | GG | 0.70 (0.46–1.05) | 0.091 | 0.117 | 0.68 (0.45–1.03) | 0.070 | 0.154 | 0.54 (0.32–0.90) | 0.014* | 0.052 | 0.69 (0.46–1.03) | 0.070 | 0.264 |
GA/AA | 0.69 (0.46–1.05) | 0.088 | 0.69 (0.46–1.04) | 0.077 | 0.53 (0.32–0.89) | 0.013* | 0.68 (0.46–1.02) | 0.066 | ||||||
rs3025039 | VEGFA | CC | 2.08 (1.34–3.23) | < 0.001* | 0.028* | 1.40 (0.93–2.10) | 0.100 | 0.107 | 0.99 (0.65–1.52) | 0.960 | 0.950 | 1.42 (0.96–2.11) | 0.073 | 0.178 |
CT/TT | 2.08 (1.34–3.23) | 0.0007* | 1.43 (0.95–2.16) | 0.080 | 0.99 (0.64–1.51) | 0.950 | 1.40 (0.95–2.08) | 0.089 | ||||||
rs7292407 | PPARA | CC | 0.68 (0.45–1.01) | 0.058 | 0.160 | 0.71 (0.48–1.05) | 0.091 | 0.264 | 0.80 (0.50–1.26) | 0.330 | 0.493 | 0.72 (0.49–1.06) | 0.094 | 0.160 |
AC/AA | 0.70 (0.46–1.04) | 0.080 | 0.68 (0.46–1.02) | 0.066 | 0.81 (0.51–1.29) | 0.370 | 0.73 (0.49–1.08) | 0.120 |
a adjusted for age, BMI and smoking status. * P < 0.05 indicted significant difference. Q-value was calculated using Benjamini and Hochberg method in multiple hypothesis testing including above 4 SNPs. AMS Acute mountain sickness; HD Headache; DL Dizziness and light-headedness; GI Gastrointestinal symptoms; FA Fatigue and/or weakness; OR Odds ratio; CI Confidence interval